- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05620836
Badanie mające na celu ocenę skuteczności i bezpieczeństwa stosowania povorcytynibu (INCB054707) u uczestników z umiarkowanym do ciężkiego ropnym zapaleniem apokrynowych gruczołów potowych (HS) (STOP-HS2)
Badanie III fazy, podwójnie ślepej próby, randomizowane, kontrolowane placebo, dotyczące skuteczności i bezpieczeństwa stosowania povorcytynibu (INCB054707) u uczestników z umiarkowanym do ciężkiego ropnym zapaleniem apokrynowych gruczołów potowych
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
New South Wales
-
Kogarah, New South Wales, Australia, 02217
- Investigative Site AU205
-
Kotara, New South Wales, Australia, 02289
- Investigative Site AU203
-
Liverpool, New South Wales, Australia, 02170
- Investigative Site AU200
-
-
Queensland
-
Benowa, Queensland, Australia, 04217
- Investigative Site AU202
-
Woolloongabba, Queensland, Australia, 04102
- Investigative Site AU206
-
Woolloongabba, Queensland, Australia, 04102
- Investigative Site AU207
-
-
Victoria
-
Carlton, Victoria, Australia, 03053
- Investigative Site AU201
-
Melbourne, Victoria, Australia, 03002
- Investigative Site AU204
-
-
-
-
-
Sofia, Bułgaria, 01407
- Investigative Site BG203
-
Sofia, Bułgaria, 01463
- Investigative Site BG202
-
Sofia, Bułgaria, 01510
- Investigative Site BG200
-
Sofia, Bułgaria, 01606
- Investigative Site BG204
-
Stara Zagora, Bułgaria, 06000
- Investigative Site BG201
-
-
-
-
-
Roskilde, Dania, 04000
- Investigative Site DK201
-
Århus N, Dania, 08200
- Investigative Site DK200
-
-
-
-
-
Antony, Francja, 92160
- Investigative Site FR200
-
Dijon, Francja, 21000
- Investigative Site FR205
-
Lyon, Francja, 69003
- Investigative Site FR204
-
Nice, Francja, 06200
- Investigative Site FR203
-
Reims, Francja, 51100
- Investigative Site FR206
-
Rouen, Francja, 76031
- Investigative Site FR202
-
Toulon, Francja, 83000
- Investigative Site FR201
-
-
-
-
-
Alicante, Hiszpania, 03010
- Investigative Site ES203
-
Las Palmas de Gran Canaria, Hiszpania, 35019
- Investigative Site ES202
-
Madrid, Hiszpania, 28005
- Investigative Site ES204
-
Madrid, Hiszpania, 28007
- Investigative Site ES201
-
Madrid, Hiszpania, 28040
- Investigative Site ES205
-
Manises, Hiszpania, 46940
- Investigative Site ES200
-
-
-
-
-
St. John's, Kanada, A1A 4Y3
- Investigative Site CA203
-
-
Alberta
-
Calgary, Alberta, Kanada, T3E 0B2
- Investigative Site CA202
-
Edmonton, Alberta, Kanada, T6G 1C3
- Investigative Site CA204
-
-
British Columbia
-
Surrey, British Columbia, Kanada, V3V 0C6
- Investigative Site CA200
-
-
New Brunswick
-
Fredericton, New Brunswick, Kanada, E3B 1G9
- Investigative Site CA205
-
-
Ontario
-
Mississauga, Ontario, Kanada, L4W 0C2
- Investigative Site CA207
-
Richmond Hill, Ontario, Kanada, L4C 9M7
- Investigative Site CA208
-
-
Quebec
-
Saint-Jérôme, Quebec, Kanada, J7Z 7E2
- Investigative Site CA206
-
-
-
-
-
Berlin, Niemcy, 10117
- Investigative Site DE202
-
Bochum, Niemcy, 44791
- Investigative Site DE203
-
Dessau, Niemcy, 06847
- Investigative Site DE201
-
Erlangen, Niemcy, 91054
- Investigative Site DE207
-
Göttingen, Niemcy, 37075
- Investigative Site DE208
-
Heidelberg, Niemcy, 69120
- Investigative Site DE205
-
Kiel, Niemcy, 24105
- Investigative Site DE200
-
Lübeck, Niemcy, 23538
- Investigative Site DE204
-
Mainz, Niemcy, 55131
- Investigative Site DE206
-
-
MA
-
Frankfurt am Main, MA, Niemcy, 60590
- Investigative Site US225
-
-
-
-
-
Lublin, Polska, 20573
- Investigative Site PL203
-
Rzeszów, Polska, 35-055
- Investigative Site PL200
-
Warsaw, Polska, 02-507
- Investigative Site PL201
-
Warsaw, Polska, 02-962
- Investigative Site PL202
-
-
-
-
Arizona
-
Scottsdale, Arizona, Stany Zjednoczone, 85255
- Investigative Site US240
-
Scottsdale, Arizona, Stany Zjednoczone, 85259
- Investigative Site US237
-
-
Arkansas
-
Arkansas City, Arkansas, Stany Zjednoczone, 72758
- Investigative Site US214
-
Fayetteville, Arkansas, Stany Zjednoczone, 72703
- Investigative Site US242
-
-
California
-
Los Angeles, California, Stany Zjednoczone, 90033
- Investigative Site US223
-
San Diego, California, Stany Zjednoczone, 92103
- Investigative Site US226
-
San Francisco, California, Stany Zjednoczone, 94118
- Investigative Site US222
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20060
- Investigative Site US233
-
-
Florida
-
Brandon, Florida, Stany Zjednoczone, 33511
- Investigative Site US228
-
Margate, Florida, Stany Zjednoczone, 33063
- Investigative Site US227
-
Miami, Florida, Stany Zjednoczone, 33125
- Investigative Site US204
-
Miami, Florida, Stany Zjednoczone, 33173
- Investigative Site US236
-
Ocala, Florida, Stany Zjednoczone, 34470
- Investigative Site US200
-
Tampa, Florida, Stany Zjednoczone, 33613
- Investigative Site US201
-
-
Illinois
-
West Dundee, Illinois, Stany Zjednoczone, 60118
- Investigative Site US220
-
-
Indiana
-
Indianapolis, Indiana, Stany Zjednoczone, 46250
- Investigative Site US206
-
-
Iowa
-
Iowa City, Iowa, Stany Zjednoczone, 52242
- Investigative Site US241
-
-
Kentucky
-
Louisville, Kentucky, Stany Zjednoczone, 40241
- Investigative Site US209
-
-
Louisiana
-
Metairie, Louisiana, Stany Zjednoczone, 70006
- Investigative Site US207
-
New Orleans, Louisiana, Stany Zjednoczone, 70115
- Investigative Site US229
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21224
- Investigative Site US224
-
-
Massachusetts
-
Beverly, Massachusetts, Stany Zjednoczone, 01915
- Investigative Site US208
-
Quincy, Massachusetts, Stany Zjednoczone, 02169
- Investigative Site US221
-
-
Michigan
-
Detroit, Michigan, Stany Zjednoczone, 48084
- Investigative Site US213
-
Waterford, Michigan, Stany Zjednoczone, 48328
- Investigative Site US217
-
-
Minnesota
-
Minneapolis, Minnesota, Stany Zjednoczone, 55455
- Investigative Site US212
-
-
Nebraska
-
Omaha, Nebraska, Stany Zjednoczone, 68144
- Investigative Site US239
-
-
New Jersey
-
Hightstown, New Jersey, Stany Zjednoczone, 08520
- Investigative Site US230
-
-
New York
-
New York, New York, Stany Zjednoczone, 10003
- Investigative Site US202
-
Rochester, New York, Stany Zjednoczone, 14642
- Investigative Site US210
-
-
North Carolina
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27516
- Investigative Site US205
-
-
Ohio
-
Bexley, Ohio, Stany Zjednoczone, 43209
- Investigative Site US215
-
Columbus, Ohio, Stany Zjednoczone, 43210
- Investigative Site US203
-
-
Tennessee
-
Murfreesboro, Tennessee, Stany Zjednoczone, 37130
- Investigative Site US232
-
-
Texas
-
Arlington, Texas, Stany Zjednoczone, 76011
- Investigative Site US235
-
Bellaire, Texas, Stany Zjednoczone, 77401
- Investigative Site US218
-
Pflugerville, Texas, Stany Zjednoczone, 78660
- Investigative Site US238
-
San Antonio, Texas, Stany Zjednoczone, 78213
- Investigative Site US234
-
-
-
-
-
Ancona, Włochy, 60126
- Investigative Site IT200
-
Brescia, Włochy, 25124
- Investigative Site IT204
-
Catania, Włochy, 95123
- Investigative Site IT207
-
Milan, Włochy, 20122
- Investigative Site IT202
-
Naples, Włochy, 80131
- Investigative Site IT203
-
Pisa, Włochy, 56126
- Investigative Site IT206
-
Roma, Włochy, 00168
- Investigative Site IT205
-
Rozzano, Włochy, 20089
- Investigative Site IT201
-
-
-
-
-
Birmingham, Zjednoczone Królestwo, B15 2GW
- Investigative Site GB202
-
Dudley, Zjednoczone Królestwo, DY1 2HQ
- Investigative Site GB200
-
Leeds, Zjednoczone Królestwo, LS1 3EX
- Investigative Site GB201
-
London, Zjednoczone Królestwo, SE1 7EH
- Investigative Site GB204
-
Salford, Zjednoczone Królestwo, M6 8HD
- Investigative Site GB203
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Male and female participants ≥ 18 years of age.
- Diagnosis of moderate to severe HS ≥ 3 months prior to Screening visit.
- HS lesions present in ≥ 2 distinct anatomic areas, 1 of which must be at least Hurley Stage II or Hurley Stage III, at both the Screening and Baseline visits.
- Total abscess and inflammatory nodule (AN) count ≥ 5 at both the Screening and Baseline visits.
- History of inadequate response to an appropriate course of at least 1 conventional systemic therapy for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for HS)
- Agree to not use certain topical antiseptics on the areas affected by HS lesions during the placebo-controlled period.
- Willingness to avoid pregnancy or fathering children.
- Other inclusion criteria apply.
Exclusion Criteria:
- Draining tunnel count of > 20 at Screening or Baseline visits.
- Women who are pregnant (or who are considering pregnancy) or breastfeeding.
- Medical history including thrombocytopenia, coagulopathy or platelet dysfunction; venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated herpes zoster or dermatomal herpes zoster; disseminated herpes simplex; chronic/recurrent infections; malignancies.
- Evidence of infection with TB, HBV, HCV or HIV.
- History of failure to JAK inhibitor treatment of any inflammatory disease.
- Laboratory values outside of the protocol-defined ranges.
- Other exclusion criteria apply.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Povorcitinib Dose A
Participants will receive Povorcitinib Dose A for 54 weeks. |
Oral, Tablet
Inne nazwy:
|
|
Eksperymentalny: Povorcitinib Dose B
Participants will receive Povorcitinib Dose B for 54 weeks. |
Oral, Tablet
Inne nazwy:
|
|
Komparator placebo: Placebo
Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks. |
Oral, Tablet |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 12
Ramy czasowe: Baseline; Week 12
|
HiSCR50 is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 12
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percentage of Participants Who Achieved HiSCR75 at Week 12
Ramy czasowe: Baseline; Week 12
|
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 12
|
|
Percentage of Participants With Flare by Week 12
Ramy czasowe: Baseline; Week 12
|
Participants who experienced at least 1 flare over 12 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline. |
Baseline; Week 12
|
|
Percentage of Participants With at Least a 3-point Decrease in Skin Pain Numerical Rating Scale (NRS) Score at Week 12 Among Participants With a Baseline Skin Pain NRS Score ≥3
Ramy czasowe: Baseline; Week 12
|
Participants with a Skin Pain score of at least 3 at baseline and who experienced at least a 3-point decrease in Skin Pain score at Week 12, relative to baseline, were assessed. Skin Pain was assessed using an 11-point NRS, ranging from 0 (no skin pain) to 10 (worst skin pain). |
Baseline; Week 12
|
|
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 12 Among Participants With a Baseline Skin Pain NRS Score of at Least 3
Ramy czasowe: Baseline; Week 12
|
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 12, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed. Skin Pain was assessed using an 11-point NRS, ranging from 0 (no skin pain) to 10 (worst skin pain). analyzed. |
Baseline; Week 12
|
|
Percentage of Participants With at Least a 4-point Increase From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Score at Week 12
Ramy czasowe: Baseline; Week 12
|
Participants with a baseline FACIT-F score ≤48 and who experienced at least a 4-point increase in FACIT-F score at Week 12, relative to baseline, were assessed. The FACIT-F scale is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days, with scores for each item ranging from 0 (worst fatigue) to 4 (no fatigue). The total score is a sum of the 13 item scores and ranges from 0 (worst fatigue) to 52 (no fatigue). |
Baseline; Week 12
|
|
Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Ramy czasowe: Baseline; up to Week 54
|
The DLQI is a 10-question, validated questionnaire that measures how much the skin problem has affected the participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relations, and treatment. Each question is scored as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. Change from baseline was calculated as the post-baseline value minus the baseline value. Scores from each question are summed to produce a total score, ranging from 0 (not relevant) to 30 (very much). A higher score reflects a greater negative impact on quality of life. |
Baseline; up to Week 54
|
|
Mean Change From Baseline in DLQI Score at Each Visit During the Extension Period
Ramy czasowe: Baseline; up to Week 54
|
The DLQI is a 10-question, validated questionnaire that measures how much the skin problem has affected the participant over the previous 7 days, across symptoms and feelings, daily activities, leisure, work and school, personal relations, and treatment. Each question is scored as follows: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. Change from baseline was calculated as the post-baseline value minus the baseline value. Scores from each question are summed to produce a total score, ranging from 0 (not relevant) to 30 (very much). A higher score reflects a greater negative impact on quality of life. |
Baseline; up to Week 54
|
|
Mean Change From Baseline in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Ramy czasowe: Baseline; up to Week 54
|
Change from baseline was calculated as the post-baseline value minus the baseline value. |
Baseline; up to Week 54
|
|
Mean Change From Baseline in Abscess Count at Each Visit During the Extension Period
Ramy czasowe: Baseline; up to Week 54
|
Change from baseline was calculated as the post-baseline value minus the baseline value. |
Baseline; up to Week 54
|
|
Percentage Change From Baseline (PCFB) in Abscess Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Ramy czasowe: Baseline; up to Week 54
|
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100. |
Baseline; up to Week 54
|
|
Percentage Change From Baseline in Abscess Count at Each Visit During the Extension Period
Ramy czasowe: Baseline; up to Week 54
|
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100. |
Baseline; up to Week 54
|
|
Mean Change From Baseline in Inflammatory Nodule Count at Each Visit at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Ramy czasowe: Baseline; up to Week 54
|
Change from baseline was calculated as the post-baseline value minus the baseline value. |
Baseline; up to Week 54
|
|
Mean Change From Baseline in Inflammatory Nodule Count at Each Visit During the Extension Period
Ramy czasowe: Baseline; up to Week 54
|
Change from baseline was calculated as the post-baseline value minus the baseline value. |
Baseline; up to Week 54
|
|
Percentage Change From Baseline in Inflammatory Nodule Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Ramy czasowe: Baseline; up to Week 54
|
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100. |
Baseline; up to Week 54
|
|
Percentage Change From Baseline in Inflammatory Nodule Count at Each Visit During the Extension Period
Ramy czasowe: Baseline; up to Week 54
|
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100. |
Baseline; up to Week 54
|
|
Mean Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Ramy czasowe: Baseline; up to Week 54
|
Change from baseline was calculated as the post-baseline value minus the baseline value. |
Baseline; up to Week 54
|
|
Mean Change From Baseline in Draining Tunnel Count at Each Visit During the Extension Period
Ramy czasowe: Baseline; up to Week 54
|
Change from baseline was calculated as the post-baseline value minus the baseline value. |
Baseline; up to Week 54
|
|
Percentage Change From Baseline in Draining Tunnel Count at Each Visit During the Placebo-controlled Period and the Overall Study (for Participants Who Took Only Povorcitinib)
Ramy czasowe: Baseline; up to Week 54
|
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100. |
Baseline; up to Week 54
|
|
Percentage Change From Baseline in Draining Tunnel Count at Each Visit During the Extension Period
Ramy czasowe: Baseline; up to Week 54
|
Percentage change from baseline was calculated as (post-baseline value minus the baseline value) divided by the baseline value x 100. |
Baseline; up to Week 54
|
|
Percentage of Participants Who Achieved HiSCR50 at Week 24 for Participants Who Took Only Povorcitinib
Ramy czasowe: Baseline; Week 24
|
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 24
|
|
Percentage of Participants Who Achieved HiSCR50 at Week 24 During the Extension Period
Ramy czasowe: Baseline; Week 24
|
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 24
|
|
Percentage of Participants Who Achieved HiSCR75 at Week 24 for Participants Who Took Only Povorcitinib
Ramy czasowe: Baseline; Week 24
|
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 24
|
|
Percentage of Participants Who Achieved HiSCR75 at Week 24 During the Extension Period
Ramy czasowe: Baseline; Week 24
|
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 24
|
|
Percentage of Participants With Flare by Week 24 for Participants Who Took Only Povorcitinib
Ramy czasowe: Baseline; up to Week 24
|
Participants who experienced at least 1 flare over 24 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline. |
Baseline; up to Week 24
|
|
Percentage of Participants With Flare by Week 24 During the Extension Period
Ramy czasowe: Baseline; up to Week 24
|
Participants who experienced at least 1 flare over 24 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline. |
Baseline; up to Week 24
|
|
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 24 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib
Ramy czasowe: Baseline; Week 24
|
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 24, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed. |
Baseline; Week 24
|
|
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 24 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 3
Ramy czasowe: Baseline; Week 24
|
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 24, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed. |
Baseline; Week 24
|
|
Percentage of Participants Who Achieved HiSCR50 at Week 54 for Participants Who Took Only Povorcitinib
Ramy czasowe: Baseline; Week 54
|
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 54
|
|
Percentage of Participants Who Achieved HiSCR50 at Week 54 During the Extension Period
Ramy czasowe: Baseline; Week 54
|
HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 54
|
|
Percentage of Participants Who Achieved HiSCR75 at Week 54 for Participants Who Took Only Povorcitinib
Ramy czasowe: Baseline; Week 54
|
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 54
|
|
Percentage of Participants Who Achieved HiSCR75 at Week 54 During the Extension Period
Ramy czasowe: Baseline; Week 54
|
HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
Baseline; Week 54
|
|
Percentage of Participants With Flare by Week 54 for Participants Who Took Only Povorcitinib
Ramy czasowe: Baseline; up to Week 54
|
Participants who experienced at least 1 flare over 54 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline. |
Baseline; up to Week 54
|
|
Percentage of Participants With Flare at Week 54 During the Extension Period
Ramy czasowe: Baseline; up to Week 54
|
Participants who experienced at least 1 flare over 54 weeks were assessed. Flare is defined as at least a 25% increase in the total AN count with a minimum increase of 2 relative to baseline. |
Baseline; up to Week 54
|
|
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 54 Among Participants With Baseline Skin Pain NRS Score of at Least 3 and Who Took Only Povorcitinib
Ramy czasowe: Baseline; Week 54
|
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 54, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed. |
Baseline; Week 54
|
|
Percentage of Participants Who Achieved Skin Pain NRS30 at Week 54 During the Extension Period Among Participants With Baseline Skin Pain NRS Score of at Least 3
Ramy czasowe: Baseline; Week 54
|
Participants with a Skin Pain score of at least 3 at baseline and who achieved Skin Pain NRS30 at Week 54, defined as at least a 30% reduction and at least a 1-unit reduction from baseline in the Skin Pain NRS, were assessed. |
Baseline; Week 54
|
|
Percentage of Participants Who Achieved Maintenance of HiSCR50 or Greater Response During the Extension Period for Participants Who Took Only Povorcitinib
Ramy czasowe: up to 42 weeks (from end of Week 12 to end of Week 54)
|
Maintenance of response is defined as achieving HiSCR50 at Week 12 and maintaining it or achieving greater response at each visit during the extension period. HiSCR50 is defined as at least a 50% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
up to 42 weeks (from end of Week 12 to end of Week 54)
|
|
Percentage of Participants Who Achieved Maintenance of HiSCR75 or Greater Response During the Extension Period for Participants Who Took Only Povorcitinib
Ramy czasowe: up to 42 weeks (from end of Week 12 to end of Week 54)
|
Maintenance of response is defined as achieving HiSCR75 at Week 12 and maintaining it or achieving greater response at each visit during the extension period. HiSCR75 is defined as at least a 75% reduction from baseline in the total AN count, with no increase from baseline in abscess or draining tunnel count. |
up to 42 weeks (from end of Week 12 to end of Week 54)
|
|
Placebo-controlled Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Ramy czasowe: up to Week 16
|
An adverse event (AE) is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. |
up to Week 16
|
|
Placebo-controlled Period: Number of Participants With ≥Grade 3 TEAEs
Ramy czasowe: up to Week 16
|
A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal. |
up to Week 16
|
|
Extension Period: Number of Participants With TEAEs
Ramy czasowe: up to 46 weeks (from end of Week 12 to end of Week 58)
|
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. |
up to 46 weeks (from end of Week 12 to end of Week 58)
|
|
Extension Period: Number of Participants With ≥Grade 3 TEAEs
Ramy czasowe: up to 46 weeks (from end of Week 12 to end of Week 58)
|
A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute CTCAE version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal. |
up to 46 weeks (from end of Week 12 to end of Week 58)
|
|
Overall Study Period: Number of Participants Who Took Only Povorcitinib With TEAEs
Ramy czasowe: up to Week 58
|
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not it is considered drug related. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. |
up to Week 58
|
|
Overall Study Period: Number of Participants Who Took Only Povorcitinib With ≥Grade 3 TEAEs
Ramy czasowe: up to Week 58
|
A TEAE is any AE, either reported for the first time or the worsening of a pre-existing event, occurring after the first dose of study drug until 30 days after the last dose of study drug. Severity of AEs was graded using the National Cancer Institute CTCAE version 5.0. Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal. |
up to Week 58
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- INCB 54707-302
- 2022-501753-36-00 (Identyfikator rejestru: EU CT Number)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Ramy czasowe udostępniania IPD
Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Kryteria dostępu do udostępniania IPD
Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .